Radiotherapy in the management of unresectable locally advanced pancreatic cancer: A survey of the current UK practice of clinical oncologists

Clinical Oncology

Volumn 22, Issue 4, 2010, Pages 257-260

  Saleem, A ^a   Jackson, A ^a   Mukherjee, S ^b   Stones, N ^a   Crosby, T ^b   Tait, D ^c   Price, P ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b VELINDRE CANCER CENTRE   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

ACORRN; Locally advanced pancreatic cancer; National radiotherapy trials; Pancreatic cancer; Radiotherapy; Survey

Indexed keywords

CAPECITABINE; CETUXIMAB; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; NELFINAVIR; UFT;

ARTICLE; CANCER RADIOTHERAPY; CANCER RESEARCH; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; ONCOLOGY; ONLINE SYSTEM; OVERALL SURVIVAL; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; QUESTIONNAIRE; RADIATION DOSE FRACTIONATION; TREATMENT PLANNING; TUMOR LOCALIZATION; TUMOR VOLUME; UNITED KINGDOM;

CLINICAL TRIALS AS TOPIC; GREAT BRITAIN; HEALTH SURVEYS; HUMANS; MEDICAL ONCOLOGY; PANCREATIC NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 77951765458     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.02.004     Document Type: Article

References (9)

1. Sener S.F., Fremgen A., Menck H.R., Winchester D.P. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999, 189(1):1-7.
2. Mukherjee S., Hudson E., Reza S., Thomas M., Crosby T., Maughan T. Pancreatic cancer within a UK cancer network with special emphasis on locally advanced non-metastatic pancreatic cancer. Clin Oncol (R Coll Radiol) 2008, 20(7):535-540.
3. Huguet F., Andre T., Hammel P., et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007, 25(3):326-331.
4. Brunner T.B., Geiger M., Grabenbauer G.G., et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2008, 26(16):2699-2706.
5. Heap G., Stones N. Networking to deliver research: research radiographers within the Academic Clinical Oncology and Radiobiology Research Network (ACORRN). J Radiother Pract 2009, 8:87-92.
6. Boeck S., Bruns C.J., Sargent M., et al. Current oncological treatment of patients with pancreatic cancer in Germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the German Cancer Society. Oncology 2009, 77(1):40-48.
7. Kim S., Russell W., Price P., Saleem A. Suboptimal use of intravenous contrast during radiotherapy planning in the UK. Br J Radiol 2008, 81(972):963-969.
8. Vaishampayan U.N., Ben-Josef E., Philip P.A., et al. A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. Int J Radiat Oncol Biol Phys 2002, 53(3):675-679.
9. Huguet F., Girard N., Guerche C.S., Hennequin C., Mornex F., Azria D. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009, 27(13):2269-2277.